Literature DB >> 27464865

Depression and anxiety in patients with hematological malignancies, prevalence, and associated factors.

Khadega A Abuelgasim1, Gasmelseed Y Ahmed, Jamilah A Alqahtani, Aseel M Alayed, Ahmed S Alaskar, Mansoor A Malik.   

Abstract

OBJECTIVES: To study the prevalence and associated factors of depression and anxiety in hematological cancers (HC) patients.
METHODS: We conducted a cross-sectional survey in all HC patients at King Abdulaziz Medical City (KAMC), Riyadh, Saudi Arabia between March 2014 and June 2015. We excluded patients with depression, or generalized anxiety disorder. We conducted a structured face to face interview using an internally developed and validated questionnaire (Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 patient's questionnaire with all participants).
RESULTS: Among 211 participants, depression was detected in 98 (46.5%) and anxiety was detected in 47 (22.3%). Thirty-eight (18.1%) had concurrent anxiety and depression. Multiple co-morbidities and tense home atmosphere were predictive for anxiety and depression. We found no association between gender, smoking, income, or being on active therapy and depression or anxiety.
CONCLUSIONS: Depression and anxiety are highly prevalent in HC patients in KAMC. Health care providers should screen HC cancers for depression and anxiety; as early intervention possibly improve their disease outcome and will likely enhance their psychological wellbeing.

Entities:  

Mesh:

Year:  2016        PMID: 27464865      PMCID: PMC5018705          DOI: 10.15537/smj.2016.8.14597

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


The emotional well-being of cancer patients is terribly affected by depression.1 Adults cancer patients have very high prevalence of both anxiety and depression.2 The prevalence of depression in cancer patients is more than in stroke patients, and patients with heart disease.3 Depressed cancer patients suffer, they participate less in medical care, and they require longer hospitalization periods compared to those who are not depressed.4 A significant percentage of patients with hematological cancers (HC) receives high dose chemotherapy and requires long periods of hospitalization. Hematological cancers patients who undergo hematopoietic stem cell transplant are even at a higher risk for depression and anxiety.5 Non-medical factors such as personal traits, lower level of education, lower socioeconomic status, family conflicts and lack of family support are contributory factors to patient’s emotional disturbance. Derogatis et al6 first attempted to study the prevalence of psychiatric disorders in cancer patients using DSM-III in 1983. Among 215 cancer patients, 47% had evidence of at least one psychiatric disorder. Sixty-eight percent had adjustment disorder with depressed, or anxious mood. Thirteen percent were qualified for major depression.6 Both improvement in survival and increased incidence of most cancer types increase the prevalence of depression and anxiety in such patients’ population. It is important to identify psychiatric disorders in cancer patients; depression and anxiety are of particular importance as they generally lead to poor adherence to treatment, and therefore worse disease outcome.7-9 Health care providers play a major role in screening, providing first line treatment, and referring patients for further evaluation and treatment for these conditions. Unfortunately, they are often over worked, busy and mostly not sufficiently trained to perform a proper psychological assessment. As a result, these mental disorders may go undetected and may lead to poor patients’ outcome, longer recovery time and greater use of health care resources.10 Data from the Middle East2,11-13 pertinent was scanty, and studies were carried out mainly in patients with solid tumors. Given the different epidemiology of different types of cancers and the unique ethnic makeover and unique culture of the region, we elected to study the prevalence and associated factors of depression and anxiety in HC patients attending the King Abdulaziz Medical City (KAMC) Oncology Center, Riyadh, Saudi Arabia. We believe it is important to bring these important issues to the attention of health care providers caring for those patients.

Methods

We conducted our literature review by conducting multiple Pub Med search using the terms: depression, anxiety, hematological cancer, Middle East, and Saudi Arabia. Our study was a cross-sectional survey and was conducted according to the principles of Helsinki. The sample for categorical data formula was applied to calculate the optimal number of participants for this study. An effect size of depression in 17.8% and anxiety in 16.8% within cancer patients from a similar study was applied to obtain a sample capable of detecting statistical results with 95% levels of confidence and only 0.05 margin of error.8 After obtaining the approval from the King Abdullah International Medical Research Center Institutional Review Board, all patients >14 years with confirmed HC admitted to the hematology ward, or attended hematology clinic at KAMC, Riyadh were approached between March 2014 and June 2015, and were asked to participate in the study. Hematological cancers include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) were illegible. We included patients who are actively receiving therapy as well as those who have completed their therapy. Patients who are known to have depression, or generalized anxiety disorder were excluded. After obtaining the informed consent from the patient, or the patient’s guardian in patients younger than age 18, a structured face to face clinical interview was conducted by one of our trained research assistants. An internally developed and validated questionnaire was used to collect demographic, social, and financial data. Participants were also asked to self-report the type of HC they have and whether, or not they are actively receiving therapy for their cancer. The Diagnostic and Statistical Manual of Mental Disorders-Third Edition (DSM-III), generally used to screen non-psychiatric patients for the presence of different psychiatric disorders, has many tools; among them are Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionaire-9 (PHQ-9).14 The GAD-7 standardized questionnaire, translated to Arabic language was used in our study to screen participants for anxiety.15-18 It is a 7-item self-report scale with a score ranging from 0-3 for each question, providing 0-21 severity score. A score of 5-9 is a cut-off point to identify cases of mild generalized anxiety disorder, a score of 10 is a cut-off point for identifying cases with moderate GAD, while a score of 15 is indicative of severe GAD. We only reported moderate and severe GAD. The PHQ-9 standardized questionnaire designed for use in non-psychiatric clinical settings and in research, translated into Arabic language was used to screen participants for depression.15-17 The PHQ-9 includes 9 items designed to screen for feeling worthless, or guilty, anhedonia, trouble focusing, low mood, sleep related troubles, fatigue, appetite disturbances, feeling slow or irritable and suicidal ideation. It has a 0-27 severity score. A cut-off point of 10 was used to identify depression in our study. After completion of data collection and accuracy check, data was transferred into an excel sheet and subsequently reviewed, and verified for consistency. The Statistical Analysis Software SAS version 9.2. (SAS Institute Inc., Cary, NC, USA) was applied for data analysis and a p-value ≤0.05 was accepted as significant. Categorical variables were presented as counts and percentages, while continuous variables were reported as median with interquartile. Univariate analysis test was applied to study the association between mental health disorders and participants’ characteristics.

Results

A total of 211participants were enrolled in the study. shows the demographic and clinical characteristics. The median age of participants was 46 years (27-64). Using a cut-off score of 10, which represent moderate anxiety and depression in GAD-7 and PHQ-9 assessment scales, depression was detected in 98 (46.5%), and anxiety in 47 (22.3%) participants. Combined anxiety and depression were found in 38 (18.1%). Univariate analysis of associated factors anxiety and depression is presented in Tables . Participants’ characteristics of 211 enrolled in the study. Univariate analysis of 211 participants with anxiety enrolled in the study. Univariate analysis of 211 participants with depression enrolled in the study.

Discussion

Hematological cancer patients are more likely to require intensive therapies, and at times prolonged hospitalization, compared with patients with solid tumors. This can have significant impact on their emotional wellbeing and can increase their susceptibility to physical and mental stress, and perhaps affect their disease outcome.22 The prevalence of anxiety in HC patients were reported to be between 20% and 37%.23 Our study showed that 22.3% of Saudi HC suffers from anxiety. Such highly significant percentage requires active and continuous screening in order to early diagnose, and refer patients to receive the appropriate therapy. Depression has been linked to altered immunity and lower survival rates in non-cancer patients.24-26 Altered immunity can adversely affect cancer patients; this is of particular importance in HC patients receiving high dose chemotherapy. Effective treatment of depression in cancer patients has been linked to improvement in patients’ adjustment to stress and decrement in the magnitude of their symptoms leading to better disease outcome at a lower cost.27 The prevalence of depression in our cohort was 46.5%; a bit on the higher side compared with the international reported rates of 17-51%. This is particularly concerning, as it has been shown that approximately 40% of patients with depression and cancer have suicidal thoughts on direct questioning; however, most people with depression are neither detected, nor treated.28 It is not clear to us why depression is highly prevalent in our cohort. Coexisting anxiety and depression are found in 12-15% of HC patients and may result in more suffering and possibly worse outcome.23,29,30 In our cohort, this prevalence was even higher at 18.1%. Al Zaben et al13 recently reported association of low education, low socio-economic status and young age, and the presence of anxiety in Saudi breast cancer patients. Several other demographic, clinical and socioeconomic factors were linked to higher chance of developing anxiety, or depression in cancer patients. Among these factors are: gender, marital status, cancer type and stage, time since diagnosis, type of therapy received, being on active therapy, history of smoking, home atmosphere and family support.1,11,13,23,30-32 While other studies showed no correlation between some of these factors with depression, or anxiety.2,23 In our study, tense home atmosphere and the presence of co-morbidities were significantly associated with higher prevalence of both anxiety and depression, regardless of other factors. Depression and anxiety are prevalent in cancer free patients with medical problems such as diabetes, stroke, and heart disease.3,33 The effect of co-morbidities can be explained by the fact that cancer patients with co-morbidities perceive themselves as sick unlike those who previously healthy. In our study, lack of education was not found to be associated with anxiety contradicting what Al-Zaben et al13 found in Western Saudi Arabia breast cancer patients, but it was rather associated with depression. That can be explained by regional differences as our facility is located in the Central region. We found a trend of less anxiety among married participants; however the difference from unmarried was not statistically significant. Although smoking was not very prevalent in our cohort, we found no association between smoking history and depression or anxiety. One would expect that patients receiving active therapy experience more psychological stress compared with those with completed their therapy; this was not proven in our cohort. One explanation could be that cancer patients always feel threatened and expect disease relapse at anytime, therefore, the stress continues throughout their lives regardless of their disease status.

Study limitations

First, this is a single institution’s study; therefore, our results may not be representing all Saudi HC patients. Second: one quarter of our participants was illiterate, although not representative of the Saudi population, that could have affected the comprehension of the questionnaires presented to those participants. The prevalence of anxiety in this patients’ population seems to be in the same range compared with what is reported in the regional and international studies. Relatively higher prevalence of depression among this patients’ population is of a particular concern. Health care providers ought to screen HC patients for depression and anxiety since early referral and intervention may not only improve their psychological wellbeing, but also their disease outcome.
Table 1

Participants’ characteristics of 211 enrolled in the study.

Table 2

Univariate analysis of 211 participants with anxiety enrolled in the study.

Table 3

Univariate analysis of 211 participants with depression enrolled in the study.

  30 in total

1.  Gender differences in factors associated with suicidal ideation in major depression among cancer patients.

Authors:  Tatsuo Akechi; Hitoshi Okamura; Tomohito Nakano; Nobuya Akizuki; Masako Okamura; Ken Shimizu; Toru Okuyama; Toshiaki A Furukawa; Yosuke Uchitomi
Journal:  Psychooncology       Date:  2010-04       Impact factor: 3.894

2.  Predicting psychological distress in patients with leukaemia and lymphoma.

Authors:  Charles Montgomery; Marilyn Pocock; Kirsten Titley; Keith Lloyd
Journal:  J Psychosom Res       Date:  2003-04       Impact factor: 3.006

3.  Influence of psychological response on survival in breast cancer: a population-based cohort study.

Authors:  M Watson; J S Haviland; S Greer; J Davidson; J M Bliss
Journal:  Lancet       Date:  1999-10-16       Impact factor: 79.321

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 5.  Cancer and depression.

Authors:  D Spiegel
Journal:  Br J Psychiatry Suppl       Date:  1996-06

6.  Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies.

Authors:  Fábio R M Santos; Elisa H Kozasa; Maria de Lourdes L F Chauffaille; Gisele W B Colleoni; Jose Roberto Leite
Journal:  J Psychosom Res       Date:  2006-05       Impact factor: 3.006

7.  Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population.

Authors:  Bernd Löwe; Oliver Decker; Stefanie Müller; Elmar Brähler; Dieter Schellberg; Wolfgang Herzog; Philipp Yorck Herzberg
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

8.  Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients?

Authors:  F Romito; R Montanaro; C Corvasce; M Di Bisceglie; V Mattioli
Journal:  Support Care Cancer       Date:  2007-12-11       Impact factor: 3.603

9.  Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors.

Authors:  K L Pinder; A J Ramírez; M E Black; M A Richards; W M Gregory; R D Rubens
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases.

Authors:  Martin Härter; Harald Baumeister; Katrin Reuter; Frank Jacobi; Michael Höfler; Jürgen Bengel; Hans-Ulrich Wittchen
Journal:  Psychother Psychosom       Date:  2007       Impact factor: 17.659

View more
  8 in total

1.  Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study.

Authors:  Abebe Muche Belete; Anmut Alemagegn; Anemut Tilahun Mulu; Taklo Simeneh Yazie; Bekalu Bewket; Adisu Asefa; Wendimeneh Shibabaw Shiferaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

2.  Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies.

Authors:  Smita Chandra; Vibha Gupta; Harish Chandra; Mohan Dhyani; Aarti Kotwal; Sanjiv Kumar Verma; Ravi Gupta
Journal:  J Neurosci Rural Pract       Date:  2019 Jan-Mar

3.  Prevalence and Associated Factors of Depressive Symptoms in Patients with Myasthenia Gravis: A Cross-Sectional Study of Two Tertiary Hospitals in Riyadh, Saudi Arabia.

Authors:  Mohammed H Alanazy
Journal:  Behav Neurol       Date:  2019-09-15       Impact factor: 3.342

4.  The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China.

Authors:  Mianmian Gu; Xiaohong Hao; Lin Cong; Jie Sun
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study.

Authors:  Sheng-Min Wang; Sung-Soo Park; Si-Hyun Park; Nak-Young Kim; Dong Woo Kang; Hae-Ran Na; Jong Wook Lee; Seunghoon Han; Hyun Kook Lim
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

6.  Global, regional, and national prevalence of depression among cancer patients: A systematic review and meta-analysis.

Authors:  Zahra Noorani Mejareh; Bahare Abdollahi; Zahra Hoseinipalangi; Melika Shamsian Jeze; Hossein Hosseinifard; Sima Rafiei; Farnaz Aghajani; Afsaneh Dehnad; Mohadeseh Fadavi Ardakani; Saba Ahmadi; Haniyeh Anbarhassani; Mahsa Tohidi Asl; Fatemeh Pashazadeh Kan; Aidin Aryankhesal; Hosein Shabaninejad; Sepideh Aghalou; Ahmad Ghashghaee
Journal:  Indian J Psychiatry       Date:  2021-12-03       Impact factor: 1.759

7.  Predicting anxiety in cancer survivors presenting to primary care - A machine learning approach accounting for physical comorbidity.

Authors:  Markus W Haun; Laura Simon; Halina Sklenarova; Verena Zimmermann-Schlegel; Hans-Christoph Friederich; Mechthild Hartmann
Journal:  Cancer Med       Date:  2021-06-02       Impact factor: 4.452

8.  Quality of life and distress assessed with self and external assessment screening tools in patients with hematologic malignancies attending treatment in an acute hospital.

Authors:  Bianca Senf; Kirsten Grabowski; Natascha Spielmann; Jens Fettel
Journal:  Qual Life Res       Date:  2020-08-19       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.